BG
PBLS

Bellevue Group’s Parabilis Medicines Inc PBLS Stock Holding History

Bellevue Group’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7M Buy
+500,000
New +$13.8M 0.29% 64

Other funds holding PBLS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bellevue Group's PBLS Position: Q2 2026 in Review

Bellevue Group opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 500,000 shares worth $13.7M. The stake represents 0.29% of the portfolio and ranks #64 among its holdings.

58 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

  • Bellevue Group held 500,000 shares of Parabilis Medicines Inc worth $13.7M as of Q2 2026.
  • Parabilis Medicines Inc was a new Bellevue Group position in Q2 2026.
  • Parabilis Medicines Inc made up 0.29% of Bellevue Group's portfolio in Q2 2026, its #64 holding.
  • 58 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.